Menu
Oslo, Norway, 12 June 2026 – Thor Medical ASA announces that Mathias Nilsen Reierth, Head of Communications & Corporate Affairs and a primary insider of the company, has purchased 27,777 shares in the company at an average price of NOK 4.14 per share.
Notification of the transaction in accordance with the Market Abuse Regulation Article 19 is attached to this announcement.
For further information please contact:
Brede Ellingsæter
Chief Financial Officer
Tel: +47 472 38 440
Email: brede.ellingseter@thormedical.no
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
Tel: +47 988 05 724
Email: mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of alpha particle emitters produced from naturally occurring thorium, a key component of next-generation targeted cancer treatment. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides a reliable, environmentally friendly and cost-efficient supply of alpha emitters to the radiopharmaceutical industry. Guided by its vision to become a world-leading enabler for targeted cancer therapies, Thor Medical is committed to improving millions of lives by fueling next-generation cancer therapies with high-purity isotopes. Thor Medical is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under the ticker symbol TRMED. For more information, visit www.thormedical.com. - http://www.thormedical.com
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.
